Page 1 of Clinical Trials for Drug PD 0332334, 14 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Withdrawn
A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects
Last Updated: February 16, 2010
Condition(s): Generalized Anxiety Disease
2
Terminated
Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
Last Updated: May 29, 2009
Condition(s): Anxiety Disorders
3
Terminated
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
Last Updated: February 16, 2010
Condition(s): Generalized Anxiety Disorder
4
Completed
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
Last Updated: February 16, 2010
Condition(s): Renal Dialysis; Pharmacokinetics
5
Completed
A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
Last Updated: February 17, 2010
Condition(s): Generalized Anxiety Disorder
6
Terminated
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
Last Updated: September 14, 2010
Condition(s): Generalized Anxiety Disorder
7
Terminated
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
Last Updated: September 14, 2010
Condition(s): Generalized Anxiety Disorder
8
Terminated
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
Last Updated: September 14, 2010
Condition(s): Generalized Anxiety Disorder
9
Terminated
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
Last Updated: September 14, 2010
Condition(s): Generalized Anxiety Disorder
10
Terminated
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
Last Updated: February 16, 2010
Condition(s): Generalized Anxiety Disorder
11
Terminated
A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
Last Updated: February 16, 2010
Condition(s): Renal Insufficiency; Pharmacokinetics
12
Completed
A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
Last Updated: September 14, 2010
Condition(s): Generalized Anxiety Disorder
13
Completed
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
Last Updated: February 16, 2010
Condition(s): Generalized Anxiety Disorder
14
Terminated
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
Last Updated: September 14, 2010
Condition(s): Generalized Anxiety Disorder

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Drug+PD+0332334

Page 1 of Clinical Trials for Drug PD 0332334, 14 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About